SEEG-Guided DBS for OCD

ClinicalTrials.gov Identifier: NCT05623306

This is a dual-site, double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months.

The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of DBS surgery and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment.

The purpose of this study is to evaluate the safety, feasibility, and efficacy of a novel, personalized deep brain stimulation (DBS) therapy in two targeted brain areas, mapped using the stereoencephalography (SEEG) brain mapping technique.

We are looking for a total of 10 adult patients (five at each site) with treatment-refractory OCD. This study will be conducted in three stages, including implantation of SEEG depth electrodes for brain mapping, placement of the DBS system, and a randomized, shamcontrolled crossover trial, followed by open label treatment.

This study will be conducted at two sites in the United States, University of Pennsylvania, and University of California – San Francisco.

 

Please email [email protected] if you are interested in participating or have any questions about the study.

 

***We are currently not recruiting***

 

I WANT TO LEARN MORE ABOUT THIS STUDY